Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 of ELX-02 in Cystinosis patients carrying non-sense mutations

Trial Profile

A Phase 2 of ELX-02 in Cystinosis patients carrying non-sense mutations

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs ELX 02 (Primary)
  • Indications Cystinosis
  • Focus Therapeutic Use
  • Sponsors Eloxx Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2018 According to an Eloxx Pharmaceuticals media release, the company expects to report top-line data from this study in 2019.
    • 07 Aug 2018 According to an Eloxx Pharmaceuticals media release, IND in the U.S. for this trial is open and is in alignment with US FDA to enrol 6 patients in the trial. The company is planning to initiate this trial 4Q 2018.
    • 27 Apr 2018 According to an Eloxx Pharmaceuticals media release, the company seeks regulatory clearance to initiate Phase 2 clinical trials in cystinosis in USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top